Daiwa Securities Group Inc. Boosts Holdings in Repligen Co. (NASDAQ:RGEN)

Daiwa Securities Group Inc. lifted its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 29.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 24,046 shares of the biotechnology company's stock after buying an additional 5,466 shares during the period. Daiwa Securities Group Inc.'s holdings in Repligen were worth $3,461,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of RGEN. Resources Management Corp CT ADV bought a new position in Repligen during the 3rd quarter worth approximately $37,000. Quarry LP grew its position in Repligen by 796.7% during the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company's stock worth $40,000 after acquiring an additional 239 shares during the last quarter. UMB Bank n.a. grew its position in Repligen by 49.1% during the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 110 shares during the last quarter. Global Retirement Partners LLC grew its position in Repligen by 54.0% during the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock worth $53,000 after acquiring an additional 129 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in Repligen by 15.2% during the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company's stock worth $98,000 after acquiring an additional 90 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Analysts Set New Price Targets

Several equities analysts recently issued reports on RGEN shares. JPMorgan Chase & Co. raised their price target on Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. HC Wainwright restated a "buy" rating and set a $180.00 price target on shares of Repligen in a research report on Friday, February 21st. Canaccord Genuity Group initiated coverage on Repligen in a research report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price objective on the stock. Royal Bank of Canada lifted their price objective on Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a research report on Friday, February 21st. Finally, TD Cowen initiated coverage on Repligen in a research report on Monday, February 10th. They issued a "buy" rating and a $200.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Repligen presently has a consensus rating of "Moderate Buy" and a consensus target price of $181.00.

Repligen Stock Up 1.5 %

Shares of NASDAQ RGEN traded up $2.19 during mid-day trading on Monday, hitting $152.81. 481,630 shares of the stock traded hands, compared to its average volume of 644,089. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $200.23. The company has a market cap of $8.56 billion, a price-to-earnings ratio of -299.63, a PEG ratio of 4.54 and a beta of 0.95. The stock has a fifty day moving average price of $157.19 and a 200-day moving average price of $148.52.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. Research analysts anticipate that Repligen Co. will post 1.72 EPS for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.